Search

Your search keyword '"Annika Öhrfelt"' showing total 54 results

Search Constraints

Start Over You searched for: Author "Annika Öhrfelt" Remove constraint Author: "Annika Öhrfelt"
54 results on '"Annika Öhrfelt"'

Search Results

1. Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

2. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

3. Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease

4. Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer’s Disease

5. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson’s Disease

6. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays

7. Detection of α-Synuclein in Biological Samples Using Mass Spectrometry

8. Detection of α-Synuclein in Biological Samples Using Mass Spectrometry

9. Validation of a new assay for α-synuclein detection in cerebrospinal fluid

10. Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease

11. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

12. <scp>L</scp> ongitudinal <scp>M</scp> easurements of <scp>C</scp> erebrospinal <scp>F</scp> luid <scp>B</scp> iomarkers in <scp>P</scp> arkinson's <scp>D</scp> isease

13. Alzheimer’s disease—subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies

14. Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons

15. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease

16. The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up

17. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

18. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease

19. [P1–221]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS

20. Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease

21. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease

22. Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

23. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease

24. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease

25. Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease

26. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid

27. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid

28. Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

29. Transient Inflammation in Neurogenic Regions after Irradiation of the Developing Brain

30. Expression of Pisum sativum SAD polypeptides in production hosts and in planta: Tetrameric organization of the protein

31. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

32. S5‐01‐04: Alzbiomarker database on established and novel CSF and plasma biomarkers for Alzheimer's disease

33. Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry

34. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease

35. CSF biomarkers and clinical progression of Parkinson disease

36. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

37. Explorative and targeted neuroproteomics in Alzheimer's disease

38. P2‐101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP‐25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE

39. P1‐155: TARGETING SYNAPTIC PATHOLOGY WITH A NOVEL AFFINITY MASS SPECTROMETRY APPROACH

40. P2‐110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE

41. P1‐144: HIGH CSF A‐SYNUCLEIN IS ASSOCIATED WITH CLINICAL PROGRESSION IN PD PATIENTS

42. P1‐153: IDENTIFICATION OF LAMP2 AS A CANDIDATE BIOMARKER FOR ALZHEIMER'S DISEASE IN CEREBROSPINAL FLUID USING MASS SPECTROMETRY

43. Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach*

44. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

45. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders

46. P4‐263: Different CSF biomarker patterns in incipient Alzheimer's disease and vascular dementia

47. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid

48. Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method

49. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease

Catalog

Books, media, physical & digital resources